Subjective Endpoints in Clinical Trials: The Case for Blinded Independent Central Review

Open Access Journal of Clinical Trials - New Zealand
doi 10.2147/oajct.s50283
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa UK Limited

Related search

Design and Endpoints for Clinical Trials in Primary Sclerosing Cholangitis

Hepatology
MedicineHepatology
2018English

Defining Surrogate Endpoints for Clinical Trials in Severe Falciparum Malaria

PLoS ONE
Multidisciplinary
2017English

Patients’ Preferences for Selection of Endpoints in Cardiovascular Clinical Trials

Journal of Community Hospital Internal Medicine Perspectives
Internal Medicine
2014English

Development of Standard Clinical Endpoints for Use in Dengue Interventional Trials

PLoS Neglected Tropical Diseases
PharmacologyPublic HealthEnvironmentalToxicologyInfectious DiseasesPharmaceuticsOccupational Health
2018English

A Perspective on Surrogate Endpoints in Controlled Clinical Trials

Statistical Methods in Medical Research
Health Information ManagementEpidemiologyStatisticsProbability
2004English

Exploring Novel Endpoints for Clinical Trials in Kidney Disease: Challenges and Opportunities

Kidney International Reports
Nephrology
2017English

Critical Design Considerations for Time-To-Event Endpoints in Amyotrophic Lateral Sclerosis Clinical Trials

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

Surrogate Endpoints in Liver Surgery Related Trials: A Systematic Review of the Literature

HPB
HepatologyGastroenterology
2013English

Biased Safety Reporting in Blinded Randomized Clinical Trials: Meta-Analysis of Angiotensin Receptor Blocker Trials

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy